Prime Highlights:
Over 30 years of experience in biotech and pharma, with a focus on immunology and immuno-oncology.
Founder of OSE Immunotherapeutics, a clinical-stage biotech company advancing novel immunotherapies.
Key leadership in developing Tedopi, an advanced cancer vaccine showing efficacy after checkpoint inhibitor failure.
Key Background:
Dominique Constantini, a trailblazer in the field of immuno-oncology, has dedicated her career to exploring unmet clinical needs and advancing innovative therapies. With over 30 years of experience in biotech and pharma, Constantini has led pioneering efforts in immunology, allergology, and oncology.
Her journey began in the 1980s during her medical studies in Paris, where she was inspired by the necessity of understanding disease mechanisms. After joining Sanofi, she moved into senior management roles, contributing to the development and registration of products in immunology, infectiology, inflammation, and vaccines. A notable achievement was founding her first public biotech company focused on supportive care drugs for oncology, leading to the registration of three products across global markets.
However, Constantini’s true passion lay in immuno-oncology, a field that was still in its infancy when she shifted her focus. Early in her career, immuno-oncology was more of an aspiration than a reality, with research lagging behind the potential. Yet, Constantini was undeterred, believing in the promise of immune system-based cancer treatments. In 2010, breakthrough innovations like cancer vaccines and checkpoint inhibitors brought this vision closer to reality.
In 2012, Constantini founded OSE Immunotherapeutics, a company now at the forefront of immuno-oncology and immuno-inflammation. Their lead asset, Tedopi, is currently in Phase 3 trials for metastatic lung cancer, demonstrating promising efficacy after the failure of checkpoint inhibitors.
Her company’s strategic partnerships with major pharma players, such as AbbVie and Boehringer Ingelheim, underscore its potential to accelerate immunotherapy development, with a pipeline that could generate significant financial returns. Constantini’s career is defined by her passion for innovation and her drive to meet the clinical needs of cancer patients. Through her leadership, OSE Immunotherapeutics is well-positioned to shape the future of immuno-oncology.
